Most Read Articles
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.
16 Sep 2020
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab

Normal alanine aminotransferase protects against hepatic events in CHB patients

24 Sep 2018

In patients with chronic hepatitis B (CHB) infections on nucleos(t)ide analogue (NA) treatment, normal on-treatment alanine aminotransferase (ALT) levels are associated with lower risks of hepatic events, a recent study has shown.

Using data from the Clinical Data Analysis and Reporting System of Hong Kong, researchers evaluated serial on-treatment ALT levels of 21,182 CHB patients (mean age 51±13 years). ALT <30 and <19 U/L in males and females, respectively, were considered as normal. Composite hepatic events, including hepatocellular carcinoma, were the study outcomes.

Of the participants, 10,438 achieved normal on-treatment ALT levels within 12 months of NA treatment, while 10,745 did not. Only a minority (3.0 percent; n=627) of the patients developed the primary study outcome of composite hepatic events over a mean follow-up period of 4.0±1.7 years. Most of these were hepatocellular carcinoma (2.4 percent; n=509).

The cumulative hepatic event rates were lower in those with normal vs elevated on-treatment ALT at different time points: 3 months (4.27 percent vs 4.76 percent; p=0.083), 6 months (3.60 percent vs 5.24 percent; p<0.001), 9 months (3.44 percent vs 5.57 percent; p<0.001) and 12 months (3.51 percent vs 5.70 percent; p<0.001).

These were confirmed in fully adjusted Cox regression analyses, which showed that the risk of composite hepatic events were significantly lower in those with normal vs elevated ALT at 3 months (adjusted hazard ratio [HR], 0.61; 95 percent CI, 0.49–0.77; p<0.001), 6 months (adjusted HR, 0.55; 0.45–0.67; p<0.001), 9 months (adjusted HR, 0.54; 0.44–0.65; p<0.001) and 12 months (adjusted HR, 0.51; 0.42–0.61; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.
16 Sep 2020
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab